{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:26:36Z","timestamp":1764174396177},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.psym.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T18:47:05Z","timestamp":1500144425000},"page":"624-632","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment"],"prefix":"10.1016","volume":"58","author":[{"given":"Maria","family":"Janda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari A.","family":"Mergenhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.psym.2017.07.003_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4254\/wjh.v9.i7.352","article-title":"Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C","volume":"9","author":"Ponziani","year":"2017","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.psym.2017.07.003_bib2","first-page":"310","article-title":"Hepatitis C virus: a review of treatment guidelines, cost-effectiveness, and access to therapy","volume":"4","author":"Lynch","year":"2016","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.psym.2017.07.003_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/SGA.0000000000000162","article-title":"Despair of treatment: a qualitative study of cirrhotic patients' perception of treatment","volume":"40","author":"Shabanloei","year":"2017","journal-title":"Gastroenterol Nurs"},{"key":"10.1016\/j.psym.2017.07.003_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the Unites States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.psym.2017.07.003_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1176\/appi.ajp.160.1.172","article-title":"Prevalence of hepatitis C among psychiatric patients in the public sector","volume":"160","author":"Dinwiddie","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.psym.2017.07.003_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients","volume":"64","author":"Backus","year":"2016","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7","key":"10.1016\/j.psym.2017.07.003_bib7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.psym.2017.07.003_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5009\/gnl.2011.5.2.117","article-title":"Chronic hepatitis C","volume":"5","author":"Jang","year":"2011","journal-title":"Gut Liver"},{"issue":"11","key":"10.1016\/j.psym.2017.07.003_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17474124.2016.1234375","article-title":"Limiting the access to direct-acting antivirals against HCV: an ethical dilemma","volume":"10","author":"Gentile","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.psym.2017.07.003_bib11","unstructured":"Wagner D. VA to outsource care for 180,000 vets with hepatitis C, 2015"},{"issue":"11","key":"10.1016\/j.psym.2017.07.003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.02.022","article-title":"Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse","volume":"13","author":"Ho","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.psym.2017.07.003_bib13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2016.8669","article-title":"Extends new hepatitis C drugs to all veterans in its health system","volume":"316","author":"Graham","year":"2016","journal-title":"J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.psym.2017.07.003_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2016.09.004","article-title":"Hepatitis C treatment: clinical issues for psychiatrists in the post-interferon era","volume":"58","author":"Chasser","year":"2017","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.psym.2017.07.003_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","article-title":"Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group","volume":"29","author":"Bonkovsky","year":"1999","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"Suppl 1","key":"10.1016\/j.psym.2017.07.003_bib16","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0168-8278(99)80411-5","article-title":"Hepatitis C virus infection: quality of life and side effects of treatment","volume":"31","author":"Foster","year":"1999","journal-title":"J Hepatol"},{"issue":"31","key":"10.1016\/j.psym.2017.07.003_bib17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4254\/wjh.v8.i31.1318","article-title":"Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment","volume":"8","author":"Tang","year":"2016","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.psym.2017.07.003_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/NUR.0000000000000170","article-title":"Social support and adherence for military veterans with hepatitis C","volume":"30","author":"Phillips","year":"2016","journal-title":"Clin Nurse Spec"},{"issue":"6","key":"10.1016\/j.psym.2017.07.003_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.drugpo.2013.05.018","article-title":"It gives me a sense of belonging: providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group","volume":"24","author":"Woolhouse","year":"2013","journal-title":"Int J Drug Policy"},{"issue":"12","key":"10.1016\/j.psym.2017.07.003_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2893.2012.01648.x","article-title":"Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients","volume":"19","author":"Charlebois","year":"2012","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.1016\/j.psym.2017.07.003_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.genhosppsych.2011.04.005","article-title":"Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?","volume":"33","author":"Patterson","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"issue":"10","key":"10.1016\/j.psym.2017.07.003_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int J Drug Policy"},{"issue":"8","key":"10.1016\/j.psym.2017.07.003_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2893.2011.01573.x","article-title":"Hepatitis C virus-specific immune responses in noninjecting drug users","volume":"19","author":"Zeremski","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.psym.2017.07.003_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix295","article-title":"Prevalence of HIV, HCV and HBV among Homeless and non-homeless United States veterans","author":"Noska","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.psym.2017.07.003_bib25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.drugpo.2015.04.012","article-title":"Beyond viral response: a prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support","volume":"26","author":"Mason","year":"2015","journal-title":"Int J Drug Policy"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318217301561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318217301561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T08:11:47Z","timestamp":1635495107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318217301561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0033318217301561"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2017.07.003","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment","name":"articletitle","label":"Article Title"},{"value":"Psychosomatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psym.2017.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Academy of Psychosomatic Medicine.","name":"copyright","label":"Copyright"}]}}